Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc. (Nasdaq: ORKA) is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies for psoriasis and other inflammatory and immunology conditions. Its lead candidate, ORKA-001, targets IL-23p19 and is being developed for psoriasis; ORKA-002 targets IL-17A and IL-17F, with… From the company’s description.
In fiscal 2025, Oruka Therapeutics, Inc. reported a net loss of $105.43M. Operations used $88.21M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Oruka Therapeutics, Inc. does
In the company’s own words
Oruka Therapeutics, Inc. (Nasdaq: ORKA) is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies for psoriasis and other inflammatory and immunology conditions. Its lead candidate, ORKA-001, targets IL-23p19 and is being developed for psoriasis; ORKA-002 targets IL-17A and IL-17F, with potential applications in psoriasis, hidradenitis suppurativa and psoriatic arthritis. Both candidates incorporate half-life extension technology intended to support less frequent dosing. The company is also developing ORKA-021, a sequential regimen combining ORKA-002 and ORKA-001, and ORKA-003, which targets an undisclosed pathway. Its programs focus on inflammatory skin diseases and related conditions, including axial spondyloarthritis. Oruka licenses rights to its antibody programs from Paragon Therapeutics. The company was formed through the 2024 acquisition of pre-merger Oruka by ARCA biopharma, which then changed its name to Oruka Therapeutics. The business is organized around its drug-development portfolio rather than reportable operating segments.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- MENLO PARK, CA
- Fiscal year end
- December
- CIK
- 907654
- SIC
- 2834
Financial performance, year by year
Fiscal 2012–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Oruka Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Oruka Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Oruka Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Oruka Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Oruka Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”